SO
ABUS icon

STRS Ohio’s Arbutus Biopharma ABUS Stock Holding History

STRS Ohio’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-10,300
Closed -$36K – 2106
2019
Q1 		$36K Hold
10,300
– – ﹤0.01% 1922
2018
Q4 		$39K Hold
10,300
– – ﹤0.01% 1911
2018
Q3 		$97K Hold
10,300
– – ﹤0.01% 1838
2018
Q2 		$75K Buy
+10,300
New +$61.3K ﹤0.01% 1910

Other funds holding ABUS

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

STRS Ohio's ABUS Position: Q2 2019 in Review

STRS Ohio sold out of Arbutus Biopharma (ABUS) in Q2 2019, closing a stake of 10,300 shares — an estimated $36K sold.

STRS Ohio first reported a position in ABUS in Q2 2018 and held it in 4 quarters. The position peaked at $97K in Q3 2018. 62 funds tracked by Wall St. Rank hold ABUS as of Q2 2019.

  • STRS Ohio reported no remaining Arbutus Biopharma position as of Q2 2019 after selling out during the quarter.
  • STRS Ohio sold 10,300 Arbutus Biopharma shares in Q2 2019, an estimated $36K.
  • STRS Ohio first reported a position in Arbutus Biopharma in Q2 2018 and held it in 4 quarters.
  • STRS Ohio's Arbutus Biopharma position peaked at $97K in Q3 2018.
  • 62 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2019.

Based on STRS Ohio's 13F filing for Q2 2019, filed 25 Jul 2019.